Jiangsu Hengrui Medicine Co., Ltd. (HKG:1276)
75.20
+2.60 (3.58%)
At close: Oct 31, 2025
Jiangsu Hengrui Medicine Revenue
Jiangsu Hengrui Medicine had revenue of 7.43B CNY in the quarter ending September 30, 2025, with 12.72% growth. This brings the company's revenue in the last twelve months to 30.98B, up 19.19% year-over-year. In the year 2024, Jiangsu Hengrui Medicine had annual revenue of 27.98B with 22.63% growth.
Revenue (ttm)
30.98B CNY
Revenue Growth
+19.19%
P/S Ratio
13.75
Revenue / Employee
1.53M CNY
Employees
20,238
Market Cap
465.52B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.98B | 5.16B | 22.63% |
| Dec 31, 2023 | 22.82B | 1.54B | 7.26% |
| Dec 31, 2022 | 21.28B | -4.63B | -17.87% |
| Dec 31, 2021 | 25.91B | -1.83B | -6.59% |
| Dec 31, 2020 | 27.73B | 4.45B | 19.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |